In the realm of dividend investing, pharmaceutical giants Pfizer and AbbVie stand out as attractive options for those seeking steady income streams.
Both companies have a history of increasing their dividends annually for over a decade. It leaves investors often wondering which stock presents a better opportunity for long-term dividend income.
This analysis delves into the dividend profiles, challenges, and growth potentials of Pfizer and AbbVie to aid income-focused investors in making an informed decision.
Read More: The Electric Future: Analyzing Rivian’s Role in the EV Market
The Appeal of Pharma Dividends
The pharmaceutical industry is not typically the first sector that comes to mind for dividend investors due to its heavy reliance on innovation and the fleeting nature of patent protections.
However, companies like Pfizer and AbbVie break the mold by offering robust dividend yields supported by a diverse portfolio of products that help mitigate the risks associated with patent expirations.
Pfizer’s Dividend Dynamics
Pfizer has demonstrated a commendable commitment to increasing its dividend, with a 61.5% rise in its payout over the last decade.
This growth, though not the fastest, coupled with a current yield of 6.2%, makes Pfizer an appealing choice for those seeking immediate high returns.
However, the company’s stock has experienced significant volatility, primarily due to the rapid rise and subsequent fall in sales of its COVID-19 products, Comirnaty and Paxlovid.
After an initial surge in sales expectations to $54 billion in 2022, projections have adjusted to $8 billion.
Despite a 72% drop in adjusted earnings per share in 2023, Pfizer’s dividend appears secure, with future earnings expected to rebound to between $2.05 and $2.25 per share in 2024.
This optimism is partly due to Pfizer’s strategic acquisition of Seagen, enhancing its cancer drug portfolio and promising substantial future revenue from drugs like Padcev.
Also Read: Investing, Swing Trading, and Day Trading: How They Are Similar and How They Differ
AbbVie’s Growth and Dividend Prospects
In contrast, AbbVie offers a lower yield of 3.6% but has a more impressive record of dividend growth, with a 269% increase since 2014. AbbVie faced its own challenges in 2023, notably the loss of U.S. patent protection for Humira, its leading product.
Despite this setback, the company’s strategic investments in new drugs like Rinvoq and Skyrizi have paid off, with combined sales of $11.7 billion last year and projections of over $27 billion by 2027.
AbbVie’s success extends to its migraine treatments, Ubrelvy and Qulipta, further diversifying its revenue streams and reinforcing its dividend growth potential.
Choosing Between Pfizer and AbbVie
For investors looking for immediate income, particularly those nearing or in retirement, Pfizer’s higher yield is an appealing option. Its stable dividend, even in the face of earnings volatility, offers a reassuring income source.
Conversely, AbbVie represents a more attractive choice for long-term investors. Its proven ability to grow dividends rapidly, combined with a promising product pipeline, suggests better dividend income potential over time.
Conclusion
The comparison between Pfizer and AbbVie underscores the importance of aligning investment choices with personal financial goals and risk tolerance. When considering Pfizer and AbbVie for dividend investing, the choice hinges on individual investment horizons and income needs.
Pfizer offers a secure, high-yield suitable for those requiring immediate income. Meanwhile, AbbVie stands out for its potential for significant dividend growth, supported by a strong pipeline of innovative treatments.
Read Next: Could IBM be a Turn-Around Stock like Microsoft?
DISCLAIMER
You should read and understand this disclaimer in its entirety before joining or viewing the website or email/blog list of SmallCapStocks.com (the “Publisher”). The information (collectively the “Advertisement”) disseminated by email, text or other method by the Publisher including this publication is a paid commercial advertisement and should not be relied upon for making an investment decision or any other purpose. The Publisher is engaged in the business of marketing and advertising the securities of publicly traded companies in exchange for compensation. The track record, gains, upside, and/or losses mentioned in the Advertisement, if any, should not be considered as true or accurate or be the basis for an investment. The Publisher does not verify the accuracy or completeness of any information included in the Advertisement. While the Publisher does not charge for the SMS service, standard carrier message and data rates may apply. To unsubscribe from receiving promotional text messages to your phone sent via an autodialer, using your phone reply to the sender’s phone number with the word STOP or HELP for help.
The Advertisement is not a solicitation or recommendation to buy securities of the advertised company. An offer to buy or sell securities can be made only by a disclosure document that complies with applicable securities laws and only in the states or other jurisdictions in which the security is eligible for sale. The Advertisement is not a disclosure document. The Advertisement is only a favorable snapshot of unverified information about the advertised company. An investor considering purchasing the securities, should always do so only with the assistance of his legal, tax and investment advisors. Investors should review with his or her investment advisor, tax advisor or attorney, if and to the extent available, any information concerning a potential investment at the web sites of the U.S. Securities and Exchange Commission (the "SEC") at www.sec.gov; the Financial Industry Regulatory Authority (the "FINRA") at www.FINRA.org, and relevant State Securities Administrator website and the OTC Markets website at www.otcmarkets.com. The Publisher cautions investors to read the SEC advisory to investors concerning Internet Stock Fraud at www.sec.gov/consumer/cyberfr.htm, as well as related information published by the FINRA on how to invest carefully. Investors are responsible for verifying all information in the Advertisement. As an advertiser, we do not verify any information we publish. The Advertisement should not be considered true or complete.
The Publisher does not offer investment advice or analysis, and the Publisher further urges you to consult your own independent tax, business, financial and investment advisors concerning any investment you make in securities particularly those quoted on the OTC Markets. Investing in securities is highly speculative and carries an extremely high degree of risk. You could lose your entire investment if you invest in any company mentioned in the Advertisement. You acknowledge that we are not an investment advisory service, a broker-dealer or an investment adviser and we are not qualified to act as such. You acknowledge that you will consult with your own independent, tax, financial and/or legal advisers regarding any decisions as to any company mentioned here. We have not determined if the Advertisement is accurate, correct or truthful. The Advertisement is compiled from publicly available information, which include, but are not limited to, no cost online research, magazines, newspapers, reports filed with the SEC or information furnished by way of press releases. Because all information relied upon by us in preparing an advertisement about an issuer comes from a public source, it is not reliable, and you should not assume it is accurate or complete.
By your subscription to our profiles, the viewing of this profile and/or use of our website, you have agreed and acknowledged the terms of our full disclaimer and privacy policy which can be viewed at the following link: www.SmallCapStocks.com/Disclaimer and www.SmallCapStocks.com/Privacy-Policy
By accepting the Advertisement, you agree and acknowledge that any hyperlinks to the website of (1) a client company, (2) the party issuing or preparing the information for the company, or (3) other information contained in the Advertisement is provided only for your reference and convenience. The advertiser is not responsible for the accuracy or reliability of these external sites, nor is it responsible for the content, opinions, products or other materials on external sites or information sources. If you use, act upon or make decisions in reliance on information contained in any disseminated report/release or any hyperlink, you do so at your own risk and agree to hold us, our officers, directors, shareholders, affiliates and agents harmless. You acknowledge that you are not relying on the Publisher, and we are not liable for, any actions taken by you based on any information contained in any disseminated email or hyperlink.
I’m Marcus Reynolds, a versatile writer known for connecting the dots between various news topics. My writing offers clear and thought-provoking insights into current events worldwide. I strive to keep you informed and engaged, making the ever-evolving world of news easier to navigate and understand.